Results 171 to 180 of about 49,721 (234)

Durable Cancer Control and Extended Long‐Term Survival Following Salvage Surgery for Squamous Cell Carcinoma of the Anal Canal: A Cohort Study

Journal of Surgical Oncology, Volume 134, Issue 4, Page 604-612, September 15, 2026.
ABSTRACT Aim Salvage surgery is the standard‐of‐care for patients with squamous cell carcinoma of the anal canal (SCCa) who experience isolated locoregional failure after upfront chemoradiotherapy. While perioperative morbidity and short‐term survival outcomes have been described, long‐term outcomes of surgical salvage are unknown.
Paul Savage, David P. Cyr, Dan E. Schiller, Bernard J. Cummings, Alexandra M. Easson, Andrew J. Smith, Carol J. Swallow   +6 more
wiley   +1 more source

Dual‐Drug‐Loaded Liposomes: Design Strategies, Mechanistic Insights, and Therapeutic Applications in Cancer

MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.
Dual‐drug‐loaded liposomes enable the simultaneous delivery of hydrophilic and hydrophobic therapeutics to tumors, enhancing anticancer efficacy and overcoming multidrug resistance. Through rational formulation design and surface functionalization, these systems improve tumor targeting, modulate efflux mechanisms and EMT, and achieve synergistic ...
Neelam Sinha, Rohan Chand Sahu, Rohit Patil, Dinesh Kumar, Ashish Kumar Agrawal   +4 more
wiley   +1 more source

Cyclins and Cyclin‐Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer

MedComm, Volume 7, Issue 9, September 2026.
This work synthesizes recent insights into the pathological roles of cyclins and cyclin‐dependent kinases (CDKs) across human cancers, highlights state‐of‐the‐art innovative approaches (especially targeted degradation and redistribution of CDK/cyclin proteins) for cancer therapy, and outlines future directions for CDK/cyclin‐related biomedical research.
Suya Zheng, Zhipeng Shen, Yuanfang Wu, Xingze Huang, Zhongyuan Zhang, Jiangyu Liu, Qichun Wei, Wenhao Chen, Ye Chen, Liang Xu   +9 more
wiley   +1 more source

Treatment of Kaposi's Sarcoma (KS) with nab-paclitaxel

Annals of Oncology, 2016
S. Fortino, M. Santoro, E. Iuliano, M. Luci, A. Perricelli, A. Pomillo   +5 more
openaire   +1 more source

Ferroptosis: Newly Emerged Regulator for Human Disease

MedComm, Volume 7, Issue 9, September 2026.
Ferroptosis is a key regulated cell death pathway closely involved in cancers, neurodegenerative disorders, acute organ injuries, and cardiovascular and chronic metabolic diseases, representing a promising therapeutic target for diverse human illnesses.
Dandan Xiao, Lin Ye, Tianqi Jiang, Mengyuan Liu, Yuxia Zhou   +4 more
wiley   +1 more source

Advances in FGF/FGFR Signaling: Implications for Disease and Therapy

MedComm, Volume 7, Issue 9, September 2026.
The FGF/FGFR signaling is indispensable for the maintenance of physiological homeostasis and governs multiple biological processes, including embryonic development, bone metabolism, angiogenesis, and neurogenesis, whereas aberrant hyperactivation of this pathway drives the progression of malignancies and autoimmune disorders, including inflammatory ...
Miaoyu Song, Xi Liu, Yang Xiao, Yongsheng Li, Huakan Zhao   +4 more
wiley   +1 more source

NSCLC: Verträglichere Therapie mit nab-Paclitaxel [PDF]

Im Focus Onkologie, 2015
openaire   +1 more source

Clinical Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy for Triple‐Negative Breast Cancer and Tumor Immune Microenvironment Analysis: A Prospective‐Retrospective Cohort Study

MedComm, Volume 7, Issue 9, September 2026.
Cohort Study Design:Between January 2019 and July 2023, 276 stage II‐III TNBC patients were enrolled in this study, including 56 in the NIC cohort and 220 in the NAC cohort. Due to 17 cases of ineligible criteria, 5 with withdrawal of informed consent, 198 patients in the NAC cohort completed NAC and underwent surgical resection.
Yongsheng Wang, Pengfei Qiu, Yuechen Wang, Xingchen Meng, Jiaxin Zhang, Haiqiang Liu, Zhiqiang Shi, Zhaopeng Zhang, Xiao Sun, Chunjian Wang, Xiangjing Meng, Chunhui Zheng   +11 more
wiley   +1 more source

Metabolism in Tumor: Mechanisms and Therapeutic Perspectives

MedComm, Volume 7, Issue 9, September 2026.
Tumor metabolic reprogramming converges on three hubs—the SREBP1/2–FASN–SCD1 lipogenic axis, the HIF‐1α–GLUT1–LDHA glycolytic axis, and the LDLR–SCARB1–LXR cholesterol system—which integrate transcriptional, epigenetic (histone lactylation, m6A), and microenvironmental inputs to generate metabolic plasticity, immune evasion, and therapy resistance ...
Jia‐Chen Cheng, Yi‐Xuan Hu, Xiang‐Chun Huang, Shan Jiang, Jie‐Lin Wang, Yang Zhao, Shuo Chen   +6 more
wiley   +1 more source

Neoadjuvant PD‐1 Blockade Tislelizumab (BGB‐A317) in Combination With Etoposide and Platinum‐Based Chemotherapy for Limited‐Disease Small Cell Lung Cancer

MedComm, Volume 7, Issue 9, September 2026.
This study assessed neoadjuvant PD‐1 blockade plus chemotherapy in patients with resectable limited‐stage small cell lung cancer. Peri‐treatment biopsy and surgical samples were analyzed using bulk RNA sequencing and bioinformatics approaches.
Shiyue Wan, Shiqi Hu, Yilv Yan, Fenghuan Sun, Dongliang Bian, Jie Luo, Dong Xie, Wenxin He, Liang Duan, Yuming Zhu, Nan Song, Ming Liu, Hongcheng Liu, Gening Jiang, Peng Zhang   +14 more
wiley   +1 more source